Compare Stocks: PSNL, STVN, SHC, and ADPT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADPT Adaptive Biotechnologies	$24.57 -0.4%	$23.32	$12.00 ▼ $26.87	$3.92B	2.09	2.30 million shs	2.16 million shs
PSNL Personalis	$16.83 +0.6%	$14.38	$4.73 ▼ $18.89	$1.76B	2.31	2.70 million shs	2.49 million shs
SHC Sotera Health	$19.03 +0.4%	$18.32	$13.09 ▼ $19.85	$5.43B	1.77	2.84 million shs	2.47 million shs
STVN Stevanato Group	€20.55 -0.9%	€20.23	€12.89 ▼ €28.00	€6.22B	0.74	530,691 shs	168,964 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADPT Adaptive Biotechnologies	+1.31%	-5.73%	+6.71%	+36.39%	+92.06%
PSNL Personalis	-1.93%	-2.05%	+26.74%	+38.26%	+247.82%
SHC Sotera Health	+1.50%	-2.97%	+5.39%	+21.77%	+17.33%
STVN Stevanato Group	+0.10%	-8.05%	-0.12%	+11.24%	-8.58%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADPT Adaptive Biotechnologies	$24.57 -0.4%	$23.32	$12.00 ▼ $26.87	$3.92B	2.09	2.30 million shs	2.16 million shs
PSNL Personalis	$16.83 +0.6%	$14.38	$4.73 ▼ $18.89	$1.76B	2.31	2.70 million shs	2.49 million shs
SHC Sotera Health	$19.03 +0.4%	$18.32	$13.09 ▼ $19.85	$5.43B	1.77	2.84 million shs	2.47 million shs
STVN Stevanato Group	€20.55 -0.9%	€20.23	€12.89 ▼ €28.00	€6.22B	0.74	530,691 shs	168,964 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADPT Adaptive Biotechnologies	+1.31%	-5.73%	+6.71%	+36.39%	+92.06%
PSNL Personalis	-1.93%	-2.05%	+26.74%	+38.26%	+247.82%
SHC Sotera Health	+1.50%	-2.97%	+5.39%	+21.77%	+17.33%
STVN Stevanato Group	+0.10%	-8.05%	-0.12%	+11.24%	-8.58%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADPT Adaptive Biotechnologies	2.57	Moderate Buy	$24.42	-0.62% Downside
PSNL Personalis	2.20	Hold	$14.54	-13.63% Downside
SHC Sotera Health	2.73	Moderate Buy	$21.50	12.98% Upside
STVN Stevanato Group	3.00	Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest PSNL, STVN, SHC, and ADPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	STVN Stevanato Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/24/2026	PSNL Personalis	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$16.25
8/11/2026	SHC Sotera Health	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/7/2026	SHC Sotera Health	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$23.00 ➝ $25.00
8/7/2026	SHC Sotera Health	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$19.00 ➝ $22.00
8/7/2026	SHC Sotera Health	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$22.00 ➝ $25.00
8/7/2026	SHC Sotera Health	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$16.00 ➝ $18.00
8/4/2026	ADPT Adaptive Biotechnologies	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$20.00 ➝ $27.50
7/30/2026	ADPT Adaptive Biotechnologies	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$22.00 ➝ $25.00
7/30/2026	ADPT Adaptive Biotechnologies	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$20.00 ➝ $22.00
7/30/2026	ADPT Adaptive Biotechnologies	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$25.00 ➝ $28.00

(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADPT Adaptive Biotechnologies	$276.98M	14.16	N/A	N/A	$0.94 per share	26.14
PSNL Personalis	$69.65M	25.30	N/A	N/A	$2.25 per share	7.48
SHC Sotera Health	$1.16B	4.67	$1.30 per share	14.62	$2.33 per share	8.17
STVN Stevanato Group	€1.23B	5.08	€0.88 per share	23.48	€5.95 per share	3.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADPT Adaptive Biotechnologies	-$59.50M	-$0.41	N/A	N/A	N/A	-20.73%	-36.81%	-13.77%	11/4/2026 (Estimated)
PSNL Personalis	-$81.27M	-$1.09	N/A	N/A	N/A	-153.84%	-46.47%	-35.30%	11/3/2026 (Estimated)
SHC Sotera Health	$77.94M	$0.57	33.39	20.03	N/A	13.44%	40.12%	7.55%	11/3/2026 (Estimated)
STVN Stevanato Group	€158.21M	€0.56	36.70	25.37	1.70	10.99%	10.43%	6.16%	N/A

Latest PSNL, STVN, SHC, and ADPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	SHC Sotera Health	$0.2389	$0.26	+$0.0211	$0.19	$309.70 million	$321.38 million
8/5/2026	Q2 2026	STVN Stevanato Group	€0.15	€0.14	-€0.01	€0.08	N/A	€302.00 million
8/4/2026	Q2 2026	PSNL Personalis	-$0.2633	-$0.30	-$0.0367	-$0.30	$16.69 million	$22.36 million
7/29/2026	Q2 2026	ADPT Adaptive Biotechnologies	-$0.1336	-$0.25	-$0.1164	-$0.25	$65.44 million	$71.55 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADPT Adaptive Biotechnologies	N/A	N/A	N/A	N/A	N/A
PSNL Personalis	N/A	N/A	N/A	N/A	N/A
SHC Sotera Health	N/A	N/A	N/A	N/A	N/A
STVN Stevanato Group	N/A	N/A	N/A	N/A	1 Years

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADPT Adaptive Biotechnologies	2.22	4.79	4.68
PSNL Personalis	N/A	5.28	5.08
SHC Sotera Health	3.33	2.80	2.55
STVN Stevanato Group	0.21	1.61	1.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADPT Adaptive Biotechnologies	99.17%
PSNL Personalis	61.91%
SHC Sotera Health	91.03%
STVN Stevanato Group	N/A

Insider Ownership

Company	Insider Ownership
ADPT Adaptive Biotechnologies	5.70%
PSNL Personalis	4.20%
SHC Sotera Health	15.36%
STVN Stevanato Group	0.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADPT Adaptive Biotechnologies	790	159.60 million	150.50 million	Optionable
PSNL Personalis	400	104.72 million	100.32 million	Optionable
SHC Sotera Health	3,000	285.38 million	241.54 million	Optionable
STVN Stevanato Group	6,010	302.84 million	300.72 million	Optionable

PSNL, STVN, SHC, and ADPT Headlines

Recent News About These Companies

Stevanato Group (STVN) Receives a Hold from Morgan Stanley

September 2 at 7:48 AM | theglobeandmail.com

Bank of America Corp DE Sells 784,125 Shares of Stevanato Group S.p.A. $STVN

September 2 at 3:27 AM | marketbeat.com

A Look at Stevanato Group SpA (STVN) After 3.4% Decline -- GF Value $25.98 vs Price $20.71

September 1 at 10:00 PM | gurufocus.com

Stevanato Group (NYSE:STVN) Shares Gap Up - Time to Buy?

August 31 at 11:59 AM | marketbeat.com

Stevanato Group: Alina Validates The Container-To-Device Flywheel

August 29, 2026 | seekingalpha.com

Stevanato Group SpA (STVN) Shares Fall 5.7% -- What GF Score of 87 Tells Investors

August 28, 2026 | gurufocus.com

Morgan Stanley Releases a Hold Rating on Stevanato Group (STVN)

August 26, 2026 | theglobeandmail.com

Ranger Investment Management L.P. Makes New $21.44 Million Investment in Stevanato Group S.p.A. $STVN

August 24, 2026 | marketbeat.com

Royal Bank of Canada Grows Stock Position in Stevanato Group S.p.A. $STVN

August 13, 2026 | marketbeat.com

Stevanato Group Details Mid-2026 Performance and Risk Landscape in Unaudited Interim Report

August 12, 2026 | theglobeandmail.com

Stevanato Group S.p.A. (NYSE:STVN) Receives Consensus Recommendation of "Buy" from Brokerages

August 12, 2026 | marketbeat.com

Insider Selling: Stevanato Group (NYSE:STVN) Director Sells €40,642.07 in Stock

August 11, 2026 | insidertrades.com

Stevanato Group (NYSE:STVN) Director Luciano Santel Sells 2,023 Shares of Stock

August 10, 2026 | marketbeat.com

Insider Selling: Stevanato Group (NYSE:STVN) Director Sells 2,045 Shares of Stock

August 10, 2026 | marketbeat.com

Insider Selling: Stevanato Group (NYSE:STVN) CFO Sells €84,558.81 in Stock

August 10, 2026 | marketbeat.com

Stevanato Group Q2 Earnings Call Highlights

August 9, 2026 | marketbeat.com

Stevanato Group Q2 2026 Results Highlight Shift to High-Value Drug Delivery Systems

August 6, 2026 | tipranks.com

Stevanato Group S.p.A. Q2 2026 Earnings Call Summary

August 6, 2026 | finance.yahoo.com

Stevanato Group S.p.A.

August 5, 2026 | fool.com

Is Stevanato (STVN) a Solid Growth Stock? 3 Reasons to Think "Yes"

August 5, 2026 | zacks.com

335,493 Shares in Stevanato Group S.p.A. $STVN Purchased by Confluence Investment Management LLC

August 5, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PSNL, STVN, SHC, and ADPT Company Descriptions

Adaptive Biotechnologies NASDAQ:ADPT

$24.57 -0.09 (-0.36%)

As of 04:00 PM Eastern

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Personalis NASDAQ:PSNL

$16.83 +0.10 (+0.60%)

As of 04:00 PM Eastern

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.

Sotera Health NASDAQ:SHC

$19.03 +0.07 (+0.37%)

As of 04:00 PM Eastern

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems. The company also provides microbiological and analytical chemistry testing, as well as technical assistance, regulatory consulting, and advisory services. It serves medical devices, pharmaceuticals, food safety, agricultural products, cancer treatment, and high-performance materials industries, as well as commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.

Stevanato Group NYSE:STVN

€20.55 -0.18 (-0.87%)

As of 03:58 PM Eastern

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PSNL, STVN, SHC, and ADPT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PSNL, STVN, SHC, and ADPT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PSNL, STVN, SHC, and ADPT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PSNL, STVN, SHC, and ADPT Company Descriptions

Adaptive Biotechnologies NASDAQ:ADPT

Personalis NASDAQ:PSNL

Sotera Health NASDAQ:SHC

Stevanato Group NYSE:STVN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PSNL, STVN, SHC, and ADPT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PSNL, STVN, SHC, and ADPT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PSNL, STVN, SHC, and ADPT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PSNL, STVN, SHC, and ADPT Company Descriptions

Adaptive Biotechnologies NASDAQ:ADPT

Personalis NASDAQ:PSNL

Sotera Health NASDAQ:SHC

Stevanato Group NYSE:STVN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools